

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. FILING DATE FIRST NAMED INVENTOR CONFIRMATION NO. APPLICATION NO. 10/723,589 11/25/2003 UCAL-243 7570 Stanley B. Prusiner 24353 02/28/2006 **EXAMINER** 7590 **BOZICEVIC, FIELD & FRANCIS LLP** WEDDINGTON, KEVIN E 1900 UNIVERSITY AVENUE ART UNIT PAPER NUMBER SUITE 200 EAST PALO ALTO, CA 94303 1614

DATE MAILED: 02/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/723,589	PRUSINER ET AL.			
		Examiner	Art Unit			
		Kevin E. Weddington	1614			
Period fo	The MAILING DATE of this communication or Preply	appears on the cover sheet with the o	correspondence address			
WHIC - Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REICHEVER IS LONGER, FROM THE MAILING rations of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. If period for reply is specified above, the maximum statutory period for reply will, by state to reply within the set or extended period for reply will, by state eply received by the Office later than three months after the managed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tire of will apply and will expire SIX (6) MONTHS from tute, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on					
~=	• • • • • • • • • • • • • • • • • • • •	· · · · · · · · · · · · · · · · · · ·				
3)	Since this application is in condition for allow		osecution as to the merits is			
,	closed in accordance with the practice unde	·				
Dispositi	on of Claims					
4)⊠	Claim(s) 1-28 is/are pending in the applicati	on.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
6)□	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)🖂	Claim(s) <u>1-28</u> are subject to restriction and/o	or election requirement.				
Applicati	on Papers					
9)	The specification is objected to by the Exam	iner.				
10)	The drawing(s) filed on is/are: a) a	ccepted or b) objected to by the	Examiner.			
	Applicant may not request that any objection to the	he drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).			
	Replacement drawing sheet(s) including the corr	ection is required if the drawing(s) is ob	ejected to. See 37 CFR 1.121(d).			
11)	The oath or declaration is objected to by the	Examiner. Note the attached Office	Action or form PTO-152.			
Priority u	ınder 35 U.S.C. § 119					
	Acknowledgment is made of a claim for forei ☐ All  b)☐ Some * c)☐ None of:	gn priority under 35 U.S.C. § 119(a	)-(d) or (f).			
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
	application from the International Bure					
* S	ee the attached detailed Office action for a l	ist of the certified copies not receive	ed.			
Attachment	• •					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4)				
3) 🔲 Inforr	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 No(s)/Mail Date		Patent Application (PTO-152)			

Application/Control Number: 10/723,589			Page 2
Art Unit: 1614	 	 	

## **DETAILED ACTION**

Due to the complex nature of the claims, no request for an oral election is being made. Please see MPEP 812.01.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-16 are drawn to a method of treating disease resulting from malformed proteins form a mammal comprising administering to said mammal a therapeutically effective amount of a bis-cyclic compound; wherein said bis-cyclic compound is characterized by clearing malformed proteins and by an ability to cross a blood brain barrier of said mammal, classified in class 514, subclass 297.
- II. Claims 17 and 18 are drawn to a composition for treating livestock with malformed proteins comprising livestock feed and a bis-cyclic compound, classified in class 514, subclass 297.
- III. Claims 19 and 20 are drawn to a method for clearly malformed proteins from livestock with the administering of a pharmaceutically effective amount of a composition comprising livestock feed and a bis-cyclic compound, classified in class 514, subclass 297.
- IV. Claims 21 and 22 are drawn to a composition comprising livestock feed and a bis-compound comprising two tricyclic moieties covalently bound by a linking group, classified in class 514, subclass 297.

Application/Control Number:	Page 3
10/723,589	
Art Unit: 1614	

- V. Claims 24 and 25 are drawn to a composition comprising a pharmaceutically acceptable carrier and a bis-cyclic compound of general formula I (Acridine), classified in class 514, subclass 297.
- VI. Claims 26-28 are drawn to a compound, classified in class 562, various subclasses.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, that the product as claimed can be made by another and materially different process.

The six inventions are independent and distinct, each from the other as they have acquired a separate status in the art as shown by their different classification.

Further, a reference, which anticipates any one of the above invention, would neither anticipate nor make obvious of the other inventions. Each such invention is capable of supporting its own patent. For these reasons, the restriction requirement is proper.

To be complete, applicants' response must include a provisional election even though the requirement may be traverse.

The applicants are required to elect a single invention for examination purposes.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise

Application/Control Number:	Page 4
10/723,589	
Art Unit: 1614	

require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 11:00 am-7:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571)272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number:	Page 5
10/723,589	
Art Unit: 1614	

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington February 21, 2006